Related Articles
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer
Genetic alterations in lung adenocarcinoma with a micropapillary component
Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome